Gerald Fetterly, Jr.

Gerald Fetterly, Jr.

PhD

Credentials

Positions

Roswell Park Comprehensive Cancer Center
  • Adjunct Faculty
  • Department of Medicine

Background

Education and Training:

  • PhD (Pharmaceutics) State University of New York at Buffalo

Publications

Fakih MG, Wang K, Holleran JL, Litwin A, Zwiebel JA, Espinoza-Delgado I, Muindi JR, Egorin MJ, Fetterly G, Diasio RB. A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clinical cancer research 2010; 16(14):3786-3794

Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert opinion on pharmacotherapy 2010; 11(11):1943-1955

Telang U, Lal D, Zagst PD, Fetterly GJ, Wang ES. Investigation of the mechanism of aflibercept mediated modulation of doxorubicin anti-tumor effects in a preclinical model of leukemia: Development of a pharmacokinetic-pharmacodynamic model to guide combination dosing strategies. Proceedings of the American Association for Cancer Research Annual Meeting 2010;51:869

Lal D , Fetterly GJ , Wetzler M , Prey J , Murphy M , Mashtare TJ , Tian L , Lin M-H , Perez AM , Marinaro J , Demock K , Park JA , Wang ES. Aflibercept exerts antivascular effects and enhances levels of anthracycline chemotherapy in vivo in human acute myeloid leukemia models. Molecular cancer therapeutics 2010; 9(10):2737-2751

Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L. Combination effects of platinum drugs and N (1), N (11) diethylnorspermine on spermidine/spermine N (1)-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants. Cancer chemotherapy and pharmacology 2011; 67(2):401-414

Adjei AA, Chai F, Savage R, Means JA, Skupien D, Fetterly GJ, Ma W, Dy GK, Sosman JA, Puzanov I. A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. Journal of clinical oncology 2010; 28(15 Suppl.):3024

Fetterly GJ, Davis HM, Tolcher AW, De Bono JS, McIntosh T, Seetharam S, Mager DE, Takimoto CH, Puchalski TA, Zhou H. Utilizing mechanistic PK/PD modeling to simultaneously examine free CCL2, total CCL2, and CNTO 888 serum concentration time data. Journal of clinical oncology 2010; 28(15 Suppl.):3029

Iyer RV, Johnson CS, Ramnath N, Fakih M, Muindi J, Wilding GE, Tan W, Javle MM, Fetterly GJ, Trump DL. Enhanced gemcitabine (G) exposure in combination with escalating doses of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] (P) in patients with advanced malignancies. Journal of clinical oncology 2010;28(15 Suppl.):e13031

Khushalani NI, Fetterly GJ, Iyer RV, Litwin A, Brady W, Javle MM. Phase I study of sunitinib with irinotecan/5-fluorouracil/ leucovorin (FOLFIRI) for advanced gastroesophageal cancers. Journal of clinical oncology 2010; 28(15 Suppl.):TPS201

Fakih M, Egorin MJ, Fetterly GJ, Muindi J, Espinoza-Delgado IJ, Phelan JT, Kramer ZB, Yirinec B , Diasio RB. A phase I study of QD and BID vorinostat x 3 days and sFULV2 in refractory colorectal cancer and other solid tumors : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract #334

Ailawadhi S, Derby L, Natarajan R, Fetterly G, Reid M, Ramnath N. Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter ? A single-institution experience. Oncology 2009; 76(2):85-90

Fakih MG, Holleran JL, Ross ME, Rustum YM, Litwin A, Espinoza-Delgado I, Zwiebel JA, Toth K, Fetterly G, Pendyala L, Egorin MJ. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clinical cancer research 2009; 15(9):3189-3195

Khushalani NI, Brady W, Fetterly G, Prey J, Levea C, Litwin A, Grande C, Iyer R, Javle M. Continuous and intermittent vorinostat (V) in combination with folfiri in advanced upper gastrointestinal cancer (AUGC): Preliminary results of a phase I pharmacokinetic (PK) study. Annals of oncology 2010; 21(Suppl. 8):260

Brem EA, Czuczman MS, Fetterly G, Gibbs JF, Deeb G, Hoskin P, Mavis C, Knight J, Campagna R, Iqbal A, Gu J, Riaz W, Bhat S, Olejniczak SH, Tsai PC, Khubchandani S, Thudium K, Hernandez-Ilizaliturri FJ. Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. British journal of haematology 2011; 153(5):599-611

Fetterly GJ, Rubin EH, Kane MP, Fishman M, Damjanov N, Fiedler-Kelly J, Lecomte D, Grahn A, Dul JL, Sherman JW, Grasela TH, Tan AR.Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel. Clinical cancer research 2008; 14(18):5856-5863

Adjei AA, Sosman JA, Martell RE, Dy GK, Goff LW, Ma WW, Horn L, Fetterly GJ, Michael SA, Means JA, Chai F, Lamar M, Strauss GM, Chiang W, Jarboe J, Schwartz BE, Puzanov I. Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3034

Fetterly GJ, Thudium KE, Kalabus J, Murphy M, Zagst PD, Prey J, Kittleman E, Adjei AA, O'Connor TL, Blanco JG. Understanding the role of carbonyl reductase polymorphisms on doxorubicin-induced cardiotoxicity with population pharmacokinetics (PK) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):2606

Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L, Fetterly G, Barrientes S, Hong DS, Naing A. Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #3511

Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M, Phelan J, Kramer Z, Yirinec B, Diasio R. A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #4083

Fetterly GJ, Brady WE, LeVea CM, Litwin AM, Zagst PD, Prey JD, Tarquini M, Giardina MK, Iyer RV, Khushalani NI. A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC).Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e15540

Iyer R, Tennant B, Brekken R, Rivera L, Pendyala L, Wu J, Fetterly G, Johnson C, Trump D. Woodchuck hepatocellular cancer (HCC): a translational model for developing anti-angiogenic therapies for human hepatocellular cancer.Proceedings of the American Association for Cancer Research Annual Meeting2008; 49:690

Lal D, Murphy M, Prey J, Fetterly GJ, Wang ES. VEGF-Trap (aflibercept) improves systemic delivery of doxorubicin to marrow and extramedullary leukemia sites in a preclinical model. Proceedings of the American Association for Cancer Research Annual Meeting 2009; 50:484-485

Rathnasabapathy C, West K, Fetterly G, Battiwalla M, Smiley SL, Hahn T, Brown K, Arnold K, Syta M, Paplham P, Liu J, McCarthy PL. Pharmacokinetics of Mycophenolic Mofetil and Metabolites in Allogeneic Transplant: Determination of Maximum Dose Schedule and Route of Administration. Blood2009; 114(22):897

Marshall JR, Ip C, Romano K, Fetterly G, Fakih M, Jovanovic B, Perloff M, Crowell J, Davis W, French-Christy R, Dew A, Coomes M, Bergan R. Methyl selenocysteine: single-dose pharmacokinetics in men. Cancer prevention research (Philadelphia, Pa.) 2011; 4(11):1938-1944

Fakih M, Groman A, McMahon J, Romano K, Wisniewski M, Wilding G, Fetterly G, Muindi J. A Phase II Randomized Study of Two Doses of Vorinostat in Combination With 5-FU/LV in Patients With Refractory Colorectal Cancer (CRC). European journal of cancer (Oxford, England : 1990) 2011; 47(Suppl. 1):S423

Iyer R, Fetterly G, Groman A, Hutson A, Khushalani N, Mohile S, Ashton E, Litwin A, Grande C, Tomaszewski G. Sunitinib and Transarterial Chemoembolization (TACE) for Advanced Hepatocellular Carcinoma (HCC)- Final Results of a Phase 2 Trial. European journal of cancer (Oxford, England : 1990) 2011; 47(Suppl. 1):S447

Fetterly GJ, Owen JS, Stuyckens K, Passarell JA, Zannikos P, Soto-Matos A, Izquierdo MA, Perez-Ruixo JJ. Semimechanistic pharmacokinetic/pharmacodynamic model for hepatoprotective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. Cancer chemotherapy and pharmacology 2008; 62(1):135-147

Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. Journal of thoracic oncology 2012;7(2):419-426

Aras UT, Lal D, Zagst P, Fetterly GJ, Wang ES. Development of a pharmacokinetic (PK)-pharmacodynamic (PD) model to guide combination-dosing strategies of aflibercept (VEGF Trap) and doxorubicin chemotherapy in a systemic preclinical model of human acute myeloid leukemia. Proceedings of the American Association for Cancer Research Annual Meeting 2011;52:Abstract #5463

Pawaskar DK, Straubinger R, Fetterly G, Ma W, Jusko W. Physiologically based pharmacokinetic model for interactions of sorafenib and everolimus in mice. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #27

Thudium KE, Haese JD, Karpf A, Fetterly G, Wetzler M. Synergistic effects of clofarabine and decitabine in acute myeloid leukemia. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #5380

Thudium KE, Telang U, Wang P, Diegelman P, Buitrago S, Curtain L, Kurenova E, Cance W, Fetterly G. Pharmacokinetics (PK) and tissue penetration of the novel VEGFR-3/FAK inhibitor, Chloropyramine. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #4257

Ait-Oudhia S, Mager DE, Tomaszewski G, Groman AE, Zagst PD, Fetterly GJ, Iyer RV. Bridging sunitinib exposure to time-to-tumor progression in hepatocellular carcinoma patients with mathematical modeling of an angiogenic biomarker. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e14690

Fetterly GJ, Liu B, Senzer NN, Amaravadi RK, Schilder RJ, Martin LP, LoRusso P, Papadopoulos KP, Adjei AA, Zagst PD, McKinlay MA, Weng DE, Graham M.Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #3029

Martell RE, Puzanov I, Ma WW, Santoro A, Dy GK, Goff LW, Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Simonelli M, Chiang WM, Jarboe J, Schwartz BE, Adjei AA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. Journal of clinical oncology 2012;30(15 Suppl.):Abstract #4117

Means-Powell JA, Adjei AA, Puzanov I, Dy GK, Goff LW, Ma WW, Fetterly GJ, Michael SA, Chai F, Lamar M, Schwartz BE, Sosman JA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #8519

Puzanov I, Sosman JA, Santoro A, Martell RE, Dy GK, Goff LW, Ma WW,Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Strauss GM, Zucali PA, Chiang WM, Jarboe J, Schwartz BE, Adjei AA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4545

Antonarakis ES, Heath EI, Posadas EM, Harrison MR, Bruce JY, Yu EY, Cho SY, Wilding GE, Fetterly GJ, Hangauer DG, Kwan M-F, Dyster LM, Carducci MA, Prostate Cancer Clinical Trials Consortium (PCCTC). A phase II study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer (CRPC): A PCCTC trial : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4654

Iyer RV, Tomaszewski G, Wu YV, Kuvshinoff BW, Groman AE, Khushalani NI, Grande C, Zagst PD, Clark K, Fetterly GJ. Advanced hepatocellular carcinoma (HCC) treated with sunitinib (Su) and transarterial chemoembolization (TACE): Phase II trial final report : 2012 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2012; 30(4 Suppl.):Abstract #275

Thudium KE, Ghoshal S, Fetterly GJ, Haese JP, Karpf AR, Wetzler M.Synergism between clofarabine and decitabine through p53R2: A pharmacodynamic drug-drug interaction modeling. Leukemia research 2012;36(11):1410-1416